{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:54:33Z","timestamp":1787007273231,"version":"build-2736575974"},"reference-count":137,"publisher":"Informa UK Limited","issue":"13","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1080\/14656566.2024.2398603","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T04:17:23Z","timestamp":1724991443000},"page":"1759-1783","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacological management of chronic lymphocytic leukemia: current and emerging therapies"],"prefix":"10.1080","volume":"25","author":[{"given":"Ivan J.","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UW Medicine\/Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace T.","family":"Baek","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UW Medicine\/Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Siu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UW Medicine\/Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology Division, University of Washington School of Medicine, Seattle, WA, USA"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"e_1_3_5_3_1","volume-title":"StatPearls","author":"Mukkamalla SKR","year":"2024","unstructured":"Mukkamalla SKR, Taneja A, Malipeddi D, et al. Chronic lymphocytic leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan [cited 2023 Mar 7]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470433\/"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_5_5_1","volume-title":"Cancer facts & figures 2024","author":"American Cancer Society","year":"2024","unstructured":"American Cancer Society. Cancer facts & figures 2024. Atlanta: American Cancer Society; 2024."},{"key":"e_1_3_5_6_1","unstructured":"Cancer stat facts: leukemia-chronic lymphocytic leukemia 2010-2014. Bethesda (MD): National Cancer Institute; [cited 2018 Jan 5]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html SEER Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race\/Ethnicity: Both Sexes 18."},{"key":"e_1_3_5_7_1","unstructured":"SEER areas 2012-2014 (table 1.15). Bethesda (MD): National Cancer Institute; [cited 2018 Jan 5]. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2014\/results_merged\/topic_lifetime_risk.pdf"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.223"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01469-7"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2943"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.1946"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969460.15364.af"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174750"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001205"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17984"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00293-5"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967492.06443.0a"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279012"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021959"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000801"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018818"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174289"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008447"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967716.49281.3f"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00224-5"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.10.3554"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720704"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0388"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27110"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012775"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02283"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01181"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174603"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969488.80825.29"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007812"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0187"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09239.x"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002184"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-378505"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-775841"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0660-8"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.03.011"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-516229"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.256"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390804"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-00973-1"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012080"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.03.012"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011386"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00033"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181108"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.256388"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4108"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279033"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061857"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-023-00721-8"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401963"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03144-y"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019706"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020158"},{"key":"#cr-split#-e_1_3_5_83_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT04277637 study of bcl-2 inhibitor BGB-11417 in participants with mature B-Cell malignancies. [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_83_1.2","unstructured":"2020 Feb 20 [cited 2024 Jun 3] Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04277637"},{"key":"#cr-split#-e_1_3_5_84_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT06073821 study of sonrotoclax (BGB-11417) plus zanubrutinib (BGB-3111) compared with venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL). [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_84_1.2","unstructured":"2023 Oct 10 [cited 2024 Jun 3]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06073821"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4037"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160386"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-183071"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01353-w"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26826"},{"key":"#cr-split#-e_1_3_5_90_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03493217 a study to evaluate ICP-022 in patients with CLL\/SLL. [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_90_1.2","unstructured":"2018 Apr 10 [cited 2024 Jun 3] Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03493217"},{"key":"#cr-split#-e_1_3_5_91_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT05322733 Orelabrutinib and obinutuzumab plus FC regimen in treating newly diagnosed CLL\/SLL. [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_91_1.2","unstructured":"2022 Apr 12 [cited 2024 Jun 3] Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05322733"},{"key":"e_1_3_5_92_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT04578613 ICP-022 versus chlorambucil combined with rituximab in the treatment of untreated CLL\/SLL. 2020 Oct 8 [cited 2024 Jun 3]; [about 4 screens]. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04578613"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18418"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000969416.78092.36"},{"key":"#cr-split#-e_1_3_5_95_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03162536 a study of nemtabrutinib (MK-1026) in participants with relapsed or refractory hematologic malignancies (ARQ 531-101\/MK-1026-001). [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_95_1.2","unstructured":"2017 May 22 [cited 2024 Jun 3] Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03162536"},{"key":"e_1_3_5_96_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT05947851 a study of nemtabrutinib plus venetoclax vs venetoclax + rituximab (VR) in second-line (2L) + Relapsed\/Refractory (R\/R) chronic lymphocytic Leukemia\/Small lymphocytic lymphoma (CLL\/SLL) (MK-1026-010\/BELLWAVE-010). [about 4 screens]. 2023 Jul 17 [cited 2024 Jun 3] https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05947851"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971772.24358.c2"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180109"},{"key":"#cr-split#-e_1_3_5_99_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT05006716 a dose-escalation and expansion study of BGB-16673 in participants with B-Cell malignancies. [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_99_1.2","unstructured":"2021 Aug 16 [cited 2024 Jun 3] Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05006716"},{"key":"e_1_3_5_100_1","volume-title":"Presented at: 2024 The European Hematology Association Hybrid Congress","author":"Linton K","year":"2024","unstructured":"Linton K, Collins G, Forconi F, et al. Latest results from an ongoing first-in-human phase 1a\/b study of NX-5948, a selective Bruton\u2019s tyrosine kinase (BTK) degrader, in patients with relapsed\/refractory CLL and other B-cell malignancies. In: Presented at: 2024 The European Hematology Association Hybrid Congress; 2024 Jun 13\u201316; Madrid, Spain. Abstract S155."},{"key":"#cr-split#-e_1_3_5_101_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT05131022 a study of NX-5948 in adults with Relapsed\/Refractory B-cell malignancies. [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_101_1.2","unstructured":"2022 Apr 13 [cited 2024 Jun 30] Available from: https:\/\/clinicaltrials.gov\/study\/NCT05131022"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2018.05.018"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7556"},{"key":"#cr-split#-e_1_3_5_104_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03088878 a study of Cirmtuzumab and ibrutinib in patients with B-Cell lymphoid malignancies. [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_104_1.2","unstructured":"2017 Mar 23 [cited 2024 Jun 3] Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03088878"},{"key":"#cr-split#-e_1_3_5_105_1.1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT04501939 cirmtuzumab consolidation for treatment of patients with detectable CLL on venetoclax (venetoclax). [about 4 screens]"},{"key":"#cr-split#-e_1_3_5_105_1.2","unstructured":"2020 Aug 6 [cited 2024 Jun 3] Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04501939"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"e_1_3_5_108_1","volume-title":"Presented at: 2023 International Workshop on CLL","author":"Kater AP","year":"2023","unstructured":"Kater AP, Eradat H, Niemann CU, et al. Epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 1b\/2 EPCORE CLL-1 trial expansion cohort. In: Presented at: 2023 International Workshop on CLL; 2023 Oct 6\u20139; Boston, MA, USA. Abstract 1546171"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01302-7"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011569"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00429-z"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01898-w"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00452-7"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015014"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00220-0"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310063"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013208"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020013"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0456c1"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00455-1"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00307-0"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3163_153"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024510"},{"key":"e_1_3_5_129_1","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT03836261 study of acalabrutinib (ACP-196) in combination with venetoclax (ABT-199) with and without obinutuzumab (GA101) versus chemoimmunotherapy for Previously untreated CLL (AMPLIFY). 2019 Feb 25 [cited 2024 Jun 6]; [about 4 screens]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03836261"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7583"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2398603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T07:06:38Z","timestamp":1728630398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2398603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":137,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1080\/14656566.2024.2398603"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2398603","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}